Patents by Inventor Ajai Pal

Ajai Pal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF GENERATING NATURAL KILLER CELLS
    Publication number: 20220259563
    Abstract: Provided herein are methods of producing natural killer cells using a two-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising administering the NK cells produced by the method to an individual having the cancer or viral infection.
    Type: Application
    Filed: April 29, 2022
    Publication date: August 18, 2022
    Applicant: Celularity Inc.
    Inventors: Robert J. HARIRI, Mohammad A. Heidaran, Stephen Jasko, Lin Kang, Eric Law, Ajai Pal, Bhavani Stout, Vanessa Voskinarian-Berse, Andrew Zeitlin, Xiaokui Zhang
  • CELL COMPOSITION AND METHODS OF MAKING THE SAME
    Publication number: 20210289769
    Abstract: Provided herein are improved methods for the formulation of compositions comprising placental stem cells, and improved compositions and cell formulations produced thereby.
    Type: Application
    Filed: June 7, 2021
    Publication date: September 23, 2021
    Applicant: Celularity Inc.
    Inventors: Andy ZEITLIN, Gregory RUSSOTTI, Shuyang HE, Ajai PAL, Hong CHEN, Thomas BRIEVA, Ryan SHORR, Brian MURPHY
  • TUMOR SUPPRESSION USING HUMAN PLACENTA-DERIVED INTERMEDIATE NATURAL KILLER CELLS AND IMMUNOMODULATORY COMPOUNDS
    Publication number: 20210121452
    Abstract: Provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising contacting the tumor cells, or administering to the individual, placental perfusate, placental perfusate cells, or natural killer cells, e.g., placenta-derived intermediate natural killer cells, with an immunomodulatory compound or thalidomide.
    Type: Application
    Filed: June 2, 2020
    Publication date: April 29, 2021
    Applicant: Celularity Inc.
    Inventors: Xiaokui ZHANG, LIn KANG, Mohammad A. HEIDARAN, Stephen JASKO, Andrew ZEITLIN, Ajai PAL, Robert J. HARIRI
  • METHODS OF GENERATING NATURAL KILLER CELLS
    Publication number: 20190330592
    Abstract: Provided herein are methods of producing natural killer cells using a two-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising administering the NK cells produced by the method to an individual having the cancer or viral infection.
    Type: Application
    Filed: July 3, 2019
    Publication date: October 31, 2019
    Applicant: Celularity, Inc.
    Inventors: Robert J. HARIRI, Mohammad A. HEIDARAN, Stephen JASKO, Lin KANG, Eric LAW, Ajai PAL, Bhavani STOUT, Vanessa VOSKINARIAN-BERSE, Andrew ZEITLIN, Xiaokui ZHANG
  • CELL COMPOSITION AND METHODS OF MAKING THE SAME
    Publication number: 20190261623
    Abstract: Provided herein are improved methods for the formulation of compositions comprising placental stem cells, and improved compositions and cell formulations produced thereby.
    Type: Application
    Filed: September 21, 2018
    Publication date: August 29, 2019
    Applicant: CELULARITY, INC.
    Inventors: Andy Zeitlin, Gregory Russotti, Shuyang He, Ajai Pal, Hong J. Chen, Thomas Brieva, Thomas Brieva, Bryan Murphy
  • Cell composition and methods of making the same
    Patent number: 10104880
    Abstract: Provided herein are improved methods for the formulation of compositions comprising placental stem cells, and improved compositions and cell formulations produced thereby.
    Type: Grant
    Filed: August 20, 2009
    Date of Patent: October 23, 2018
    Assignee: CELULARITY, INC.
    Inventors: Andy Zeitlin, Gregory Russotti, Shuyang He, Ajai Pal, Hong J. Chen, Thomas Brieva, Ryan Shorr, Brian Murphy
  • METHODS OF GENERATING NATURAL KILLER CELLS
    Publication number: 20170002322
    Abstract: Provided herein are methods of producing natural killer cells using a two-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising administering the NK cells produced by the method to an individual having the cancer or viral infection.
    Type: Application
    Filed: September 12, 2016
    Publication date: January 5, 2017
    Applicant: Anthrogenesis Corporation
    Inventors: Robert J. HARIRI, Mohammad A. HEIDARAN, Stephen JASKO, Lin KANG, Eric LAW, Ajai PAL, Bhavani STOUT, Vanessa VOSKINARIAN-BERSE, Andrew ZEITLIN, Xiaokui ZHANG
  • Methods of generating natural killer cells
    Patent number: 9464274
    Abstract: Provided herein are methods of producing natural killer cells using a two-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising administering the NK cells produced by the method to an individual having the cancer or viral infection.
    Type: Grant
    Filed: November 18, 2014
    Date of Patent: October 11, 2016
    Assignee: Anthrogenesis Corporation
    Inventors: Robert J. Hariri, Mohammad A. Heidaran, Stephen Jasko, Lin Kang, Eric Law, Ajai Pal, Bhavani Stout, Vanessa Voskinarian-Berse, Andrew Zeitlin, Xiaokui Zhang
  • TUMOR SUPPRESSION USING HUMAN PLACENTAL PERFUSATE AND HUMAN PLACENTA-DERIVED INTERMEDIATE NATURAL KILLER CELLS
    Publication number: 20160287635
    Abstract: Provided herein are placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells.
    Type: Application
    Filed: November 16, 2015
    Publication date: October 6, 2016
    Applicant: ANTHROGENESIS CORPORATION
    Inventors: Robert J. Hariri, Mohammad A. Heidaran, Lin Kang, Neerav Dilip Padliya, Ajai Pal, Vanessa Voskinarian-Berse, Andrew Zeitlin, Xiaokui Zhang
  • Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
    Patent number: 9216200
    Abstract: Provided herein are placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells.
    Type: Grant
    Filed: August 13, 2012
    Date of Patent: December 22, 2015
    Assignee: Anthrogenesis Corporation
    Inventors: Robert J. Hariri, Mohammad A. Heidaran, Lin Kang, Neerav Dilip Padliya, Ajai Pal, Vanessa Voskinarian-Berse, Andrew Zeitlin, Xiaokui Zhang
  • METHODS OF GENERATING NATURAL KILLER CELLS
    Publication number: 20150072425
    Abstract: Provided herein are methods of producing natural killer cells using a two-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising administering the NK cells produced by the method to an individual having the cancer or viral infection.
    Type: Application
    Filed: November 18, 2014
    Publication date: March 12, 2015
    Applicant: ANTHROGENESIS CORPORATION
    Inventors: Robert J. HARIRI, Mohammad A. HEIDARAN, Stephen JASKO, Lin KANG, Eric LAW, Ajai PAL, Bhavani STOUT, Vanessa VOSKINARIAN-BERSE, Andrew ZEITLIN, Xiaokui ZHANG
  • TREATMENT OF RADIATION INJURY USING AMNION DERIVED ADHERENT CELLS
    Publication number: 20150023926
    Abstract: Provided herein are methods of treating individuals having suffered exposure to radiation, e.g., individuals having radiation injury, by administering to the individuals angiogenic cells from amnion, referred to as amnion derived adherent cells, or populations of and compositions comprising, such cells.
    Type: Application
    Filed: July 13, 2012
    Publication date: January 22, 2015
    Applicant: ANTHROGENESIS CORPORATION
    Inventors: Aleksandar Francki, Ajai Pal, Robert J. Hariri, Vladimir Jankovic
  • Methods of generating natural killer cells
    Patent number: 8926964
    Abstract: Provided herein are methods of producing natural killer cells using a two-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising administering the NK cells produced by the method to an individual having the cancer or viral infection.
    Type: Grant
    Filed: July 13, 2011
    Date of Patent: January 6, 2015
    Assignee: Anthrogenesis Corporation
    Inventors: Robert J. Hariri, Mohammad A. Heidaran, Stephen Jasko, Lin Kang, Eric Law, Ajai Pal, Bhavani Stout, Vanessa Voskinarian-Berse, Andrew Zeitlin, Xiaokui Zhang
  • TREATMENT OF STROKE USING ISOLATED PLACENTAL CELLS
    Publication number: 20140341867
    Abstract: Provided herein are methods for the treatment of stroke comprising administering to a stroke victim placental stem cells, populations of cells comprising placental stem cells, and/or compositions comprising placental stem cells.
    Type: Application
    Filed: August 1, 2014
    Publication date: November 20, 2014
    Inventors: Andrew Zeitlin, Ajai Pal
  • Treatment of stroke using isolated placental cells
    Patent number: 8828376
    Abstract: Provided herein are methods for the treatment of stroke comprising administering to a stroke victim placental stem cells, populations of cells comprising placental stem cells, and/or compositions comprising placental stem cells.
    Type: Grant
    Filed: August 20, 2009
    Date of Patent: September 9, 2014
    Assignee: Anthrogenesis Corporation
    Inventors: Andy Zeitlin, Ajai Pal
  • TUMOR SUPPRESSION USING HUMAN PLACENTAL PERFUSATE AND HUMAN PLACENTA-DERIVED INTERMEDIATE NATURAL KILLER CELLS
    Publication number: 20140093488
    Abstract: Provided herein are placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells.
    Type: Application
    Filed: August 13, 2012
    Publication date: April 3, 2014
    Applicant: ANTHROGENESIS CORPORATION
    Inventors: Robert J. Hariri, Mohammad A. Heidaran, Lin Kang, Neerav Dilip Padliya, Ajai Pal, Vanessa Voskinarian-Berse, Andrew Zeitlin, Xiaokui Zhang
  • TREATMENT OF RADIATION INJURY USING AMNION DERIVED ADHERENT CELLS
    Publication number: 20140072538
    Abstract: Provided herein are methods of treating individuals having suffered exposure to radiation, e.g., individuals having radiation injury, by administering to the individuals angiogenic cells from amnion, referred to as amnion derived adherent cells, or populations of, and compositions comprising, such cells.
    Type: Application
    Filed: July 12, 2013
    Publication date: March 13, 2014
    Inventors: Aleksandar Francki, Ajai Pal, Robert J. Hariri, Vladimir Jankovic
  • Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
    Patent number: 8263065
    Abstract: Provided herein are placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells.
    Type: Grant
    Filed: September 29, 2008
    Date of Patent: September 11, 2012
    Assignee: Anthrogenesis Corporation
    Inventors: Robert J. Hariri, Mohammad A. Heidaran, Lin Kang, Neerav Dilip Padliya, Ajai Pal, Vanessa Voskinarian-Berse, Andrew Zeitlin, Xiaokui Zhang
  • METHODS OF GENERATING NATURAL KILLER CELLS
    Publication number: 20120148553
    Abstract: Provided herein are methods of producing natural killer cells using a two-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising administering the NK cells produced by the method to an individual having the cancer or viral infection.
    Type: Application
    Filed: July 13, 2011
    Publication date: June 14, 2012
    Inventors: Robert J. HARIRI, Mohammad A. Heidaran, Stephen Jasko, Lin Kang, Eric Law, Ajai Pal, Bhavani Stout, Vanessa Voskinarian-Berse, Andrew Zeitlin, Xiaokui Zhang
  • TUMOR SUPPRESSION USING HUMAN PLACENTA-DERIVED INTERMEDIATE NATURAL KILLER CELLS AND IMMUNOMODULATORY COMPOUNDS
    Publication number: 20110280849
    Abstract: Provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising contacting the tumor cells, or administering to the individual, placental perfusate, placental perfusate cells, or natural killer cells, e.g., placenta-derived intermediate natural killer cells, with an immunomodulatory compound or thalidomide.
    Type: Application
    Filed: March 24, 2011
    Publication date: November 17, 2011
    Applicant: Anthrogenesis Corporation
    Inventors: Xiaokui ZHANG, Lin Kang, Mohammad A. Heidaran, Stephen Jasko, Andrew Zeitlin, Ajai Pal, Robert J. Hariri